Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 5, 2003, Pages 1153-1168

  Eichenfield, Lawrence F ^a   Beck, Lisa ^b  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b NONE

Author keywords

Ascomycin; Atopic dermatitis; Corticosteroid; Cytokines; Eczema; Elidel; In flammation; Pimecrolimus; Pruritus; T cells; Topical immunomodulator

Indexed keywords

ALLERGEN; ANTIBODY; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PIMECROLIMUS; STEROID; TACROLIMUS; TRIAMCINOLONE ACETONIDE; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ACNE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; BURN; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; ERYTHEMA; GRAFT REJECTION; HUMAN; INCIDENCE; NEPHROTOXICITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PRURITUS; SKIN ATROPHY; SKIN IRRITATION; STRIA; T LYMPHOCYTE; TELANGIECTASIA; ADOLESCENT; ADULT; ANIMAL; CHILD; DRUG SCREENING; INFANT; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; REVIEW;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DRUG EVALUATION; HUMANS; INFANT; TACROLIMUS;

EID: 0038203253     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1492     Document Type: Article

References (60)

1. Boguniewicz M, Leung DY. New concepts in atopic dermatitis. Compr Thor 1996;22:144-51.
2. Rajka G. Natural history and clinical manifestations of atopic dermatitis. Clin Rev Allergy 1986;4:3-26.
3. Sampson HA. Pathogenesis of eczema. Clin Exp Allergy 1990:20:459-67.
4. Svensson A. Hand eczema: an evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis. Acta Derm Venereol 1988;68:509-13.
5. Leung DY, Hanifin JM, Charlesworth EN. Li JT, Bernstein IL. Berger WE, et al. Disease management of atopic dermatitis: a practice parameter. Ann Allergy Asthma Immunol 1997;79:197-211.
6. Koblenzer CS. Itching and the atopic skin. J Allergy Clin Immunol 1999;104(suppl):S109-13.
7. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860-76.
8. Larsen FS. Holm NV. Henningsen K. Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986;15:487-94.
9. Laughter D, Istvan JA, Tofte SJ. Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000;43:649-55.
10. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 1999;41:72-7.
11. Boguniewicz M, Leung DYM. Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg 2001;20:217-25.
12. Eichenfield LF. Tacrolimus and pimecrolimus. Introduction. Semin Cutan Med Surg 2001;20:215-6.
13. James JM, Kagey-Sobotka A, Sampson HA. Patients with severe atopic dermatitis have activated circulating basophils. J Allergy Clin Immunol 1993;91:1155-62.
14. Dworzak MN, Froschl G, Printz D. Fleischer C, Potschger U, Fritsch G, et al. Skin-associated lymphocytes in the peripheral blood of patients with atopic dermatitis: signs of subset expansion and stimulation. J Allergy Clin Immunol 1999;103:901-6.
15. Renz H, Jujo K, Bradley KL, Domenico J, Gelfand EW. Leung DY. Enhanced 1L-4 production and 1L-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J Invest Dermatol 1992;99:403-8.
16. Yamamoto S, Hamasaki Y, Ishii E, Ichimaru T, Miyazaki S. Unbalanced production of interleukin-5 and interleukin-2 in children with atopic dermatitis. Ann Allergy Asthma Immunol 1997;78:517-23.
17. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gone expression in acute versus chronic atopic dermatitis. J Clin Invest 1994;94:870-6.
18. Hamid Q, Naseer T. Minshall E, Song YL, Boguniewicz M, Leung DY. In vivo expression of interleukin-12 and interleukin-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225-31.
19. Akdis M, Simon HU, Weigl L, Kreyden O, Blaser K, Akdis CA. Skin homing (cutaneous lymphocyte-associated antigen-positive) CDS+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol 1999;163:466-75.
20. Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 1991;78:2542-7.
21. Bruijnzee[ PL, Kuijper PH, Kapp A, Warringa RA, Betz S, Bruijnzeel-Koomen CA. The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic demlatitis. Clin Exp Allergy 1993:23:97-109.
22. Patrizi A, Guerrini V, Ricci G. Neri I. Specchia F, Masi M. The natural history of sensitizations to food and aeroallergens in atopic dermatitis: a 4-year follow-up. Pediatr Dermatol 2000;17:261-5.
23. Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999:140:264-7.
24. Ellison JA, Patel L, Ray DW, David TJ. Clayton PE. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000;105:794-9.
25. Lutgemeier MD. Lubach D. [Development and regression of dermal corticosteroid atrophy. 4. Concentration dependence of the skin thinning effect of triamcinolone acetonide]. Derm Beruf Umwelt 1987;35:55-7.
26. Oikarinen A, Autio P. New aspects of the mechanism of corticosteroid-induced dermal atrophy. Clin Exp Dermato1 1991;16:416-9.
27. Serup J. Characterization of contact dermatitis and atopy using bioengineering techniques. A survey. Acta Derm Venereol Suppl (Stockh) 1992;177:14-25.
28. Hardie RA. Waring AJ. Barnetson RS. Atrophic skin striae following the use of clobetasol propionate ointment. Practitioner 1977;219:376-8.
29. Charman CR, Morris AD, Williams HC, Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-6.
30. McAlister RO, Tofte SJ, Doyle JJ, Jackson A, Hanifin JM. Patient and physician perspectives vary on atopic dermatitis. Cuds 2002;69:461-6.
31. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K. et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997;136:76-81.
32. Dougados M, Awada H. Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988;47:127-33.
33. De Rio MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991:71:452-4.
34. Jonas S, Bechstein WO. Tullius SG. Steinmuller T. Gamm T, Neuhaus P. Indications for tacrolimus anti-rejection therapy in liver allograft recipients. Transpl Int 1996;9(suppl 1):S164-70.
35. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E. Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001;44(suppl 1):S17-27.
36. Boguniewicz M, Fiedler VC. Raimer S, Lawrence ID. Leung DY, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998;102:637-44.
37. Paller A. Eichenfield LF, Leung DY, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44(suppl 1):S47-57.
38. Protopic [prescribing information]. Deerfield, III: Fujisawa Healthcare Inc.
39. Reitamo S, Van Leent EJ. Ho V, Harper J, Ruzicka T, Kalimo K, et al. The efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-46.
40. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55.
41. Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stutz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997:137:568-76.
42. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001:20:233-41.
43. Elidel [prescribing information]. East Hanover. NJ: Novartis Pharmaceuticals Corp.
44. Grassberger M, Baumruker T, Enz A, Hiestand P. Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141:264-73.
45. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108:275-80.
46. Meingassner JG, Fahrngruber H, Bavandi A. SDZ ASM 981, in contrast to CyA and FK 506, does not suppress the primary immune response in murine allergic contact dermatitis [abstract]. J Invest Dermatol 2000:114:832.
47. Meingassner J, Hiestand P, Bigaud M, Grassberger M. Schuurman H, Tanner M, et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506 [abstract]. J Invest Dermatol 2001:117:532.
48. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a random-ized, double-blind controlled study. Br J Dermatol 2001;144:507-13.
49. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6.
50. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998:134:805-9.
51. Wahn U, Pariser D, Gottlieb AB, Kaufmann R, Eichenfield L, Lagely R, et al. Low blood concentrations of SDZ ASM 981 in infants with extensive atopic dermatitis treated with cream 1%. Poster presented at: 59th Annual Meeting of the American Academy of Dermatology; March 2-7, 2001; Washington, DC.
52. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-8.
53. Thaci D, Kaufmann R, Scott G, Ebelin ME. Consistently low blood levels of pimecrolimus (Elidel®, SDZ ASM 981) after occlusive topical treatment of chronic hand dermatitis [abstract]. J Eur Acad Dermatol Venereol 2001;15(suppl 2):196.
54. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-87.
55. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents J Am Acad Dermatol 2002;46:495-504.
56. Hanifin JM, Thurston MS, Omoto M, Cherill RJ, Tofte SJ, Graeber M, et al. The eczema area and severity index (EASI). Assessment of reliability in atopic dermatitis. Exp Dermatol 2001;10:11-8.
57. Saurat J-H. Atopic dermatitis in children. Annales Nestlé 1987;45:9-24.
58. Ho V, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, et al. Safety and efficacy of the non-steroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003;142:155-62.
59. Wahn U, Bos JD, Goodfleld M, Caputo R, Papp K, Manjra A, et al. Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
60. Kapp A, Papp K, Bingham A. Folster-Holst R, Ortonne JP, Potter PC, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-84.